Georgia's Online Cancer Information Center

Find A Clinical Trial

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 5 LDE225 for Patients With PTCH1 or SMO Mutated Tumors

Status
Active
Cancer Type
Solid Tumor
Trial Phase
Phase II
Eligibility
18 and older, Male and Female
Study Type
Treatment
NCD ID
NCT02002689
Protocol IDs
CLDE225XUS20 (primary)
Study Sponsor
Novartis Pharmaceuticals
NCI Full Details

Summary

The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study.

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.